- Positive results in the PRO 140 clinical trials should mean good news for investors, CytoDyn President Nader Pourhassan said in an interview
- CytoDyn is currently undervalued but the effectiveness and practical appeal of PRO 140 should contribute to a turning point in stock prices
- PRO 140, a single agent therapy, is proving highly effective in the treatment of HIV; CytoDyn also planning an expansion of clinical trials to certain types of cancer
The growth potential of CytoDyn Inc. (OTCQB: CYDY) is huge, company President and CEO Dr. Nader Pourhassan said in an interview with The Wall Street Transcript (http://nnw.fm/wE4oq). According to Pourhassan, CytoDyn is undervalued for the time being, but PRO 140 is expected to contribute significantly to the growth of company stock value.
Pourhassan was appointed director in 2012, and, ever since, he has been responsible for driving the opportunity of PRO 140 as a single agent therapy for HIV, from Phase II development and into Phase III trials, including the development of trial protocols and interaction with the U.S. Food and Drug Administration, the Wall Street Transcript wrote.
PRO 140 is in advanced stages of clinical development, and recently-concluded trials clearly demonstrated its anti-viral benefits. The single-agent therapy works by blocking CCR5 HIV co-receptors on T-cells. This activity disables the viral entry without having an adverse effect on the patient’s normal immune function.
Through the clinical trials, PRO 140 demonstrated additional significant advantages over other anti-viral therapies. It showed very little toxicity or side effects in treated patients, and there was also a lack of HIV resistance developing to the treatment.
According to Pourhassan, PRO 140 could potentially make it possible for patients to put away all of their HIV pills in the near future. Currently, the company works with and monitors a small group of patients who have gone four years without needing pills, solely taking PRO 140 as single agent therapy.
The administration of PRO 140 is sub-cutaneous injection. The therapy can be administered in the comfort of one’s home, adding to the practical appeal of PRO 140, Pourhassan said. PRO 140 is designed to be injected just once per week.
One more key characteristic differentiates PRO 140 from other HIV/AIDS therapies. While on other currently approved treatments, patients will face immediate consequences in the event of missing a single dose as their HIV viral loads will begin increasing; PRO 140 allows a three-day grace period during which patients will not experience ill effects.
As of October 2018, PRO 140 HIV trials have been highly successful (http://nnw.fm/64u2Y). The viral entry inhibitor demonstrated a 93 percent suppression rate at a dose of 525 milligrams following a six-week induction period. The clinical trials suggest that the higher the dosage, the quicker the response. The probability of viral rebound is also reduced.
Based on these results and research by the company and others suggesting a role for PRO 140 in preventing cancer metastasis, CytoDyn is now planning to expand the PRO 140 clinical investigation to the treatment of cancer.
To enable such an expansion, CytoDyn has hired world-renowned cancer researcher Dr. Richard Pestell as the its chief medical officer. Pestell will be joining the team in the near future to guide the PRO 140 program toward non-HIV indications.
For more information, visit the company’s website at www.CytoDyn.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire has received compensation from CytoDyn Inc. for providing certain investor relations, marketing and social media services, including the preparation of this report, and expects to receive additional compensation for such services in the future. This compensation includes a monthly program fee.
